These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9773094)

  • 21. Hyaluronic acid therapy.
    Rosier RN; O'Keefe RJ
    Instr Course Lect; 2000; 49():495-502. PubMed ID: 10829203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis.
    Pelletier JP; Lajeunesse D; Jovanovic DV; Lascau-Coman V; Jolicoeur FC; Hilal G; Fernandes JC; Martel-Pelletier J
    J Rheumatol; 2000 Dec; 27(12):2893-902. PubMed ID: 11128682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of cytokines in osteoarthritis pathophysiology.
    Fernandes JC; Martel-Pelletier J; Pelletier JP
    Biorheology; 2002; 39(1-2):237-46. PubMed ID: 12082286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How close are we to having structure-modifying drugs available?
    Hunter DJ; Hellio Le Graverand-Gastineau MP
    Rheum Dis Clin North Am; 2008 Aug; 34(3):789-802. PubMed ID: 18687283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Animal models: insights into osteoarthritis (OA) provided by the cruciate-deficient dog.
    Brandt KD
    Br J Rheumatol; 1991; 30 Suppl 1():5-9. PubMed ID: 1991241
    [No Abstract]   [Full Text] [Related]  

  • 26. Chondroprotective/structure-modifying drugs: a neverending story.
    Henrotin Y
    Reumatismo; 2006; 58 Spec No.1():15-6. PubMed ID: 23631055
    [No Abstract]   [Full Text] [Related]  

  • 27. Quantitative assessment of cartilage status in osteoarthritis by quantitative magnetic resonance imaging: technical validation for use in analysis of cartilage volume and further morphologic parameters.
    Graichen H; von Eisenhart-Rothe R; Vogl T; Englmeier KH; Eckstein F
    Arthritis Rheum; 2004 Mar; 50(3):811-6. PubMed ID: 15022323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis.
    Myers SL; Brandt KD; Burr DB; O'Connor BL; Albrecht M
    J Rheumatol; 1999 Dec; 26(12):2645-53. PubMed ID: 10606377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of clinical response to intraarticular Hylan injections -- a prospective study using synovial fluid measures, clinical outcomes, and magnetic resonance imaging.
    Anandacoomarasamy A; Bagga H; Ding C; Burkhardt D; Sambrook PN; March LM
    J Rheumatol; 2008 Apr; 35(4):685-90. PubMed ID: 18278831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical treatment of osteoarthritis in the horse - a review.
    Goodrich LR; Nixon AJ
    Vet J; 2006 Jan; 171(1):51-69. PubMed ID: 16427582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Agrecan and articular cartilage: assessment of glycosyltransferases for the restoration of cartilage matrix in osteoarthritis].
    Magdalou J; Netter P; Fournel-Gigleux S; Ouzzine M
    J Soc Biol; 2008; 202(4):281-8. PubMed ID: 19094927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis of osteoarthritis--approaches to specific therapy.
    Niethard FU
    Am J Orthop (Belle Mead NJ); 1999 Nov; 28(11 Suppl):8-10. PubMed ID: 10587246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting both cartilage and subchondral bone might be an optimal strategy for osteoarthritis therapy.
    Huang K; Zhang XW; Ma GP; Zhong FH; Zhang C
    Med Hypotheses; 2010 Feb; 74(2):395. PubMed ID: 19857932
    [No Abstract]   [Full Text] [Related]  

  • 34. Insights into the natural history of osteoarthritis provided by the cruciate-deficient dog. An animal model of osteoarthritis.
    Brandt KD
    Ann N Y Acad Sci; 1994 Sep; 732():199-205. PubMed ID: 7978791
    [No Abstract]   [Full Text] [Related]  

  • 35. Cartilage degradation: is there a place for chondroprotective agents? A symposium of the American College of Rheumatology. Cincinnati, Ohio, June 17, 1989. Proceedings.
    Semin Arthritis Rheum; 1990 Feb; 19(4 Suppl 1):1-32. PubMed ID: 2315704
    [No Abstract]   [Full Text] [Related]  

  • 36. [Piascledine in the treatment of scleroderma].
    Szczepański A; Dabrowska H; Moskalewska K
    Przegl Dermatol; 1974; 61(4):525-7. PubMed ID: 4849404
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of sequelae of radiotherapy in ORL with various vegetable oil unsaponifiable fractions].
    Desnos J; Bertrand G
    J Fr Otorhinolaryngol Audiophonol Chir Maxillofac; 1978 Feb; 27(2):139-41. PubMed ID: 147923
    [No Abstract]   [Full Text] [Related]  

  • 38. The effects of estrogen on osteoarthritis.
    Felson DT; Nevitt MC
    Curr Opin Rheumatol; 1998 May; 10(3):269-72. PubMed ID: 9608332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug prospects in osteoarthritis.
    Bird HA
    Drug Des Deliv; 1989 Jun; 4(4):263-71. PubMed ID: 2673282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Definitions and clinical experimentation of anti-osteoarthritis agents/chondro-protectors. Survey among private rheumatologists].
    Maheu E; Dropsy R
    Rev Rhum Mal Osteoartic; 1990 Oct; 57(9 ( Pt 2)):44S-50S. PubMed ID: 2080415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.